Pfizer (PFE) Won't Pursue Split
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- S&P 500 gains as investors digest positive earnings, megacap results outlook
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
Fitch Affirms Ratings on Pfizer (PFE) Amid Decision to Remain Whole
September 27, 2016 11:51 AM EDTThe added diversification that Pfizer Inc.'s (NYSE: PFE) established pharmaceuticals business provides is a relatively less important driver of its credit profile than the company's business development and capital structure, according to Fitch Ratings.
On Monday, Pfizer said it would not be splitting into two companies, delivering its decision to investors as promised prior to the end of the year. However, relative operating prospects and valuations of the two segments could... More
Moody's Affirms Pfizer's (PFE) Ratings Amid Decision Not to Split Company
September 26, 2016 2:12 PM EDTMoody's Investors Service ("Moody's") affirmed the ratings of Pfizer Inc. (NYSE: PFE) and related subsidiaries, including the A1 senior unsecured long-term rating and the Prime-1 commercial paper rating. At the same time, Moody's revised the rating outlook to stable from negative. This rating action follows the announcement that Pfizer will not pursue a split of its pharmaceutical business.
"Pfizer's decision to keep the business whole removes a key overhang to the credit profile because a split had credit negative implications," stated Michael Levesque, Moody's Senior Vice President.
"The stable rating outlook... More
